RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase.

Tumor necrosis factor-alpha (TNF-alpha), a cytokine secreted by activated monocytes/macrophages and T lymphocytes, has been implicated in several disease states, including rheumatoid arthritis, inflammatory bowel disease, septic shock, and osteoporosis. Monocyte/macrophage production of TNF-alpha is dependent on the mitogen-activated protein kinase p38. RWJ 67657 (4-[4-(4-fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridinyl)-1H-imidazol -2-yl]-3-butyn-1-ol) inhibited the release of TNF-alpha by lipopolysaccharide (a monocyte stimulus)-treated human peripheral blood mononuclear cells with an IC(50) of 3 nM, as well as the release of TNF-alpha from peripheral blood mononuclear cells treated with the superantigen staphylococcal enterotoxin B (a T cell stimulus), with an IC(50) value of 13 nM. This compound was approximately 10-fold more potent than the literature standard p38 kinase inhibitor SB 203580 in all p38 dependent in vitro systems tested. RWJ 67657 inhibited the enzymatic activity of recombinant p38alpha and beta, but not gamma or delta, in vitro and had no significant activity against a variety of other enzymes. In contrast, SB 203580 significantly inhibited the tyrosine kinases p56 lck and c-src (IC(50) = 5 microM). RWJ 67657 did not inhibit T cell production of interleukin-2 or interferon-gamma and did not inhibit T cell proliferation in response to mitogens. RWJ 67657 inhibited TNF-alpha production in lipopolysaccharide-injected mice (87% inhibition at 50 mg/kg) and in rats (91% inhibition at 25 mg/kg) after oral administration. Based on these favorable biological properties, RWJ 67657 may have use as a treatment for inflammatory diseases.

[1]  J. Siekierka,et al.  p38α Mitogen-Activated Protein Kinase Is Activated by CD28-Mediated Signaling and Is Required for IL-4 Production by Human CD4+CD45RO+ T Cells and Th2 Effector Cells , 1999, The Journal of Immunology.

[2]  A. Harken,et al.  p38 MAPK inhibition decreases TNF-alpha production and enhances postischemic human myocardial function. , 1999, The Journal of surgical research.

[3]  J. Baldassare,et al.  The role of p38 mitogen-activated protein kinase in IL-1 beta transcription. , 1999, Journal of immunology.

[4]  T. Yue,et al.  Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion. , 1999, Circulation.

[5]  I. Mellman,et al.  Defective IL‐12 production in mitogen‐activated protein (MAP) kinase kinase 3 (Mkk3)‐deficient mice , 1999, The EMBO journal.

[6]  F. Dumont,et al.  A specific inhibitor of the p38 mitogen activated protein kinase affects differentially the production of various cytokines by activated human T cells: dependence on CD28 signaling and preferential inhibition of IL-10 production. , 1999, Cellular immunology.

[7]  J. Siekierka,et al.  T cell activation signals up-regulate p38 mitogen-activated protein kinase activity and induce TNF-alpha production in a manner distinct from LPS activation of monocytes. , 1999, Journal of immunology.

[8]  J. Dean,et al.  p38 Mitogen-activated Protein Kinase Regulates Cyclooxygenase-2 mRNA Stability and Transcription in Lipopolysaccharide-treated Human Monocytes* , 1999, The Journal of Biological Chemistry.

[9]  E. A. O'neill,et al.  Molecular basis for p38 protein kinase inhibitor specificity. , 1998, Biochemistry.

[10]  S. Watson,et al.  Direct Inhibition of Cyclooxygenase-1 and -2 by the Kinase Inhibitors SB 203580 and PD 98059 , 1998, The Journal of Biological Chemistry.

[11]  E. A. O'neill,et al.  The activation state of p38 mitogen-activated protein kinase determines the efficiency of ATP competition for pyridinylimidazole inhibitor binding. , 1998, Biochemistry.

[12]  S. Kumar,et al.  SB 203580 inhibits p38 mitogen-activated protein kinase, nitric oxide production, and inducible nitric oxide synthase in bovine cartilage-derived chondrocytes. , 1998, Journal of immunology.

[13]  M. K. Meintzer,et al.  Role of p38 mitogen-activated protein kinase in HIV type 1 production in vitro. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[14]  Elizabeth J. Goldsmith,et al.  Acquisition of Sensitivity of Stress-activated Protein Kinases to the p38 Inhibitor, SB 203580, by Alteration of One or More Amino Acids within the ATP Binding Pocket* , 1998, The Journal of Biological Chemistry.

[15]  M. Su,et al.  Interferon‐γ expression by Th1 effector T cells mediated by the p38 MAP kinase signaling pathway , 1998, The EMBO journal.

[16]  Annette Gilchrist,et al.  p38 mitogen-activated protein kinase activation is required for human neutrophil function triggered by TNF-alpha or FMLP stimulation. , 1998, Journal of immunology.

[17]  S. Kassis,et al.  Pharmacological effects of SB 220025, a selective inhibitor of P38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models. , 1998, The Journal of pharmacology and experimental therapeutics.

[18]  C. Bole-Feysot,et al.  Suppression subtractive hybridization (SSH) identifies prolactin stimulation of p38 MAP kinase gene expression in Nb2 T lymphoma cells: molecular cloning of rat p38 MAP kinase. , 1998, Journal of molecular endocrinology.

[19]  E. Nishida,et al.  Activation of p38 MAP kinase pathway by erythropoietin and interleukin-3. , 1997, Blood.

[20]  J C Lee,et al.  Novel homologues of CSBP/p38 MAP kinase: activation, substrate specificity and sensitivity to inhibition by pyridinyl imidazoles. , 1997, Biochemical and biophysical research communications.

[21]  L. Rawlinson,et al.  T Cell Proliferation in Response to Interleukins 2 and 7 Requires p38MAP Kinase Activation* , 1997, The Journal of Biological Chemistry.

[22]  G. Bemis,et al.  The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase. , 1997, Chemistry & biology.

[23]  K. Tracey,et al.  The Critical Role of p38 MAP Kinase in T Cell HIV-1 Replication , 1997, Molecular medicine.

[24]  L. Tong,et al.  A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket , 1997, Nature Structural Biology.

[25]  D E Griswold,et al.  Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. , 1996, The Journal of pharmacology and experimental therapeutics.

[26]  Philip R. Cohen,et al.  SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin‐1 , 1995, FEBS letters.

[27]  Jerry L. Adams,et al.  A protein kinase involved in the regulation of inflammatory cytokine biosynthesis , 1994, Nature.

[28]  C. Dinarello,et al.  Inflammatory cytokines: interleukin-1 and tumor necrosis factor as effector molecules in autoimmune diseases , 1991, Current Biology.

[29]  K. Resch,et al.  Interleukin 1: more than a mediator between leukocytes. , 1988, Trends in pharmacological sciences.